07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Claudetect 18 regulatory update

Ganymed said it received CE Mark approval for its Claudetect 18.2 in vitro diagnostic assay to assess the expression levels of CLDN18.2 in solid tumors. The semi-quantitative immunohistochemical assay determines CLDN18.2 protein expression in formalin-fixed...